NEW YORK (GenomeWeb) – Med BioGene today announced that it is ready to initiate proceedings against its commercial partner Precision Therapeutics to enforce a C$1 million (US$920,000) milestone payment due to Med BioGene.
NEW YORK (GenomeWeb News) – Med BioGene today said that its commercial partner, Precision Therapeutics, has been certified to perform Med BioGene's lung cancer test out of Precision's Pittsburgh laboratory.
Almac Diagnostics said this week that a group led by partner Precision Therapeutics has independently validated Almac's ColDx test for stage II colorectal cancer recurrence ahead of its full commercialization in the US.
NEW YORK (GenomeWeb News) – Med BioGene today said that it and its commercial partner, Precision Therapeutics, have settled litigation with Signal Genetics and its Respira Health subsidiary, ending a dispute over an alleged breach of contract that began more than two years ago.
A prospective study slated for publication has demonstrated that Precision Therapeutics' ChemoFx test was able to predict whether ovarian cancer patients would live longer if they took a particular chemotherapy.
NEW YORK (GenomeWeb News) – Med BioGene had no revenues and a loss of $366,345, or breakeven on a per-share basis, for full-year 2012, the company disclosed in a document filed with Canadian regulators today.
NEW YORK (GenomeWeb News) – SynapDx this week said that it has received a "significant investment" from The Kraft Group that will support ongoing clinical development of its molecular diagnostic test for autism spectrum disorder.
NEW YORK (GenomeWeb News) – Syapse, a Palo Alto, Calif.-based startup developing software for interpreting next-generation sequencing data to diagnose and treat patients, has raised $3 million in Series A venture capital funding.
Precision Therapeutics and Med BioGene said this week that Precision has successfully completed previously announced clinical studies validating the use of LungExpress Dx with tissue preserved by RNAlater, a molecular fixative.